All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
For a triple-class refractory patient entering 4L therapy, how would you sequence BCMAxCD3 and GPRC5DxCD3 bispecifics?
Featured
Bookmark this article
During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Maximilian Merz, Leipzig University, Leipzig, DE. We asked, for a triple-class refractory patient entering 4L therapy, how would you sequence BCMA×CD3 (B-cell maturation antigen) and GPRC5D×CD3 (G protein-coupled receptor family C group 5 member D) bispecifics?
For a triple-class refractory patient entering 4L therapy, how would you sequence BCMAxCD3 and GPRC5DxCD3 bispecifics?
In this video interview, Maximilian Merz discusses approved BCMA- and GPRC5D-targeted bispecific antibodies elranatamab, teclistamab, and talquetamab. He outlines the adverse events and side effects related to each class of bispecific antibody, including the risk of infection and their impact on activities of daily living. Merz highlights individual patient factors, including lifestyle and hobbies, to determine an individualized treatment plan to maintain quality of life.
This interview is also available in German.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox